These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37628902)

  • 1. Crystal Structure of the Catalytic Domain of a Botulinum Neurotoxin Homologue from
    Gregory KS; Hall PR; Onuh JP; Mojanaga OO; Liu SM; Acharya KR
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628902
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium.
    Zhang S; Lebreton F; Mansfield MJ; Miyashita SI; Zhang J; Schwartzman JA; Tao L; Masuyer G; Martínez-Carranza M; Stenmark P; Gilmore MS; Doxey AC; Dong M
    Cell Host Microbe; 2018 Feb; 23(2):169-176.e6. PubMed ID: 29396040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum neurotoxin X lacks potency in mice and in human neurons.
    Gregg BM; Matsumura T; Wentz TG; Tepp WH; Bradshaw M; Stenmark P; Johnson EA; Fujinaga Y; Pellett S
    mBio; 2024 Mar; 15(3):e0310623. PubMed ID: 38347673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition.
    Arndt JW; Yu W; Bi F; Stevens RC
    Biochemistry; 2005 Jul; 44(28):9574-80. PubMed ID: 16008342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.
    Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR
    Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
    Davies JR; Rees J; Liu SM; Acharya KR
    J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
    Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
    mSphere; 2016; 1(1):. PubMed ID: 27303710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity.
    Masuyer G; Zhang S; Barkho S; Shen Y; Henriksson L; Košenina S; Dong M; Stenmark P
    Sci Rep; 2018 Mar; 8(1):4518. PubMed ID: 29540745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.
    Hanson MA; Stevens RC
    Nat Struct Biol; 2000 Aug; 7(8):687-92. PubMed ID: 10932255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design.
    Agarwal R; Binz T; Swaminathan S
    Biochemistry; 2005 Sep; 44(35):11758-65. PubMed ID: 16128577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.
    Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR
    Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
    Arndt JW; Chai Q; Christian T; Stevens RC
    Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity.
    Jin R; Sikorra S; Stegmann CM; Pich A; Binz T; Brunger AT
    Biochemistry; 2007 Sep; 46(37):10685-93. PubMed ID: 17718519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
    Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
    Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of immunodetection system for botulinum neurotoxin serotype E.
    Sarita R; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Indian J Med Res; 2018 Jun; 147(6):603-610. PubMed ID: 30168493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of the catalytic domain of the Weissella oryzae botulinum-like toxin.
    Košenina S; Masuyer G; Zhang S; Dong M; Stenmark P
    FEBS Lett; 2019 Jun; 593(12):1403-1410. PubMed ID: 31111466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Features of
    Gregory KS; Mahadeva TB; Liu SM; Acharya KR
    Toxins (Basel); 2022 May; 14(5):. PubMed ID: 35622602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme.
    Ambrin G; Kumar R; Singh BR
    Toxicon; 2018 Mar; 144():34-41. PubMed ID: 29309744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.